Thiambutosine Inhibitor

Thiambutosine was a candidate that is used for treatment,of lepromatous leprosy.

Smith TC, Richardus JH. Relapse rates in patients treated with dapsone monotherapy and combinations of dapsone and thiambutosine, thiacetazone, isoniazid and streptomycin in the pre-MDT era. Int J Lepr Other Mycobact Dis. 1994 Sep;62(3):353-8. PubMed PMID: 7525795.
Evans AT, Croft SL, Peters W, Neal RA. Antileishmanial effects of clofazimine and other antimycobacterial agents. Ann Trop Med Parasitol. 1989 Oct;83(5):447-54. PubMed PMID: 2619361.
Khan HM. Clinical therapeutic analysis of vitiligo phase--II. Bangladesh Med Res Counc Bull. 1984 Dec;10(2):71-5. PubMed PMID: 6543425.
Mikhailov P, Dimitrova I. [Leprosy in Bulgaria. Epidemiology, Clinical forms and treatment,(author's transl)]. Z Hautkr. 1981 Oct 15;56(20):1364-70. German. PubMed PMID: 7197852.

Small volumes of Thiambutosine, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5756250 is an inhibitor targeting Thiambutosine.